Skip to main content
main-content

Cardiovascular disorders

News

11-27-2020 | Cardiovascular disorders | News

Healthy lifestyle mitigates elevated heart disease risk in people with type 2 diabetes

People with type 2 diabetes have around a fourfold increased risk for heart disease relative to those without, but having a healthy lifestyle may lessen this risk, researchers report.

11-25-2020 | Empagliflozin | News

Empagliflozin LV remodeling not reliant on glucose lowering

The EMPATROPISM trial, which enrolled people without type 2 diabetes, shows reversal of left ventricular remodeling in patients with heart failure and reduced ejection fraction given empagliflozin rather than placebo.

11-25-2020 | Cardiovascular disorders | News

More than half of people with type 2 diabetes at very high CV risk

A Spanish cross-sectional study suggests that a substantial proportion of people with type 2 diabetes are at very high risk for fatal cardiovascular events and could be considered as coronary artery disease equivalent.”

Read more

Related topics

Specific

Opinion

08-06-2019 | SGLT2 inhibitors | Editorial | Article

Cardiorenal syndromes and SGLT2 inhibitor usage

Sanjay Kalra explores the intrinsic link between the cardiovascular and renal systems, focusing on whether the SGLT2 inhibitor class has a role to play in diabetic patients with cardiorenal comorbidity.

11-14-2018 | Cardiovascular outcomes | Editorial | Article

What have I learned from cardiovascular outcome trials?

Endocrinologist Sanjay Kalra considers the impact that cardiovascular outcome trials have had on the standard of diabetes care and questions what else they might accomplish in the future.

05-22-2018 | Nutritional management | Editorial | Article

UK nutrition guidelines for the prevention and management of diabetes: An update for primary care

Advisory Board member Pamela Dyson underlines the key features for healthcare professionals working in diabetes education, diabetes management, type 2 diabetes prevention, and cardiovascular risk reduction.

In depth

07-02-2019 | Dulaglutide | Podcast | Article

REWIND, DECLARE, and high-risk diabetes patients

How will the findings of the REWIND trial and the DECLARE-TIMI 58 renal outcomes analysis affect treatment decisions for high-risk diabetes patients without overt cardiovascular disease? medwireNews asks Kamlesh Khunti.

11-16-2018 | Dapagliflozin | Video | Article

Researcher comment: DECLARE-TIMI 58

DECLARE-TIMI 58 steering committee member John Wilding talks us through the trial's findings (5:49).

Journal articles and book chapters

12-13-2018 | GLP-1 agonists | Review | Article

GLP-1RAs in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Sposito AC et al. Cardiovasc Diabetol 2018; 17: 157. doi: 10.1186/s12933-018-0800-2

11-21-2018 | Cardiovascular disorders | Review | Article

Unrecognised cardiovascular disease in type 2 diabetes: Is it time to act earlier?

Schernthaner G et al. Cardiovasc Diabetol 2018; 17: 145. doi: 10.1186/s12933-018-0788-7

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

Case reports

Image Credits